Announced Wed, 7 Oct, 2026 · 14:35 IST
Sudarshan Pharma scraps plan to acquire 9.50 percent stake in US biotech firm
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-9.0%1-day move
₹38.49
prior close
₹38.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
——+0.0+0.0-9.0—————————
Up moveDown movePending
AI summary
Sudarshan Pharma Industries has terminated its proposal to acquire 9.50 percent equity shares of Med Therapy Biotechnology Inc, USA. The separate acquisition plan by promoters Hemal Mehta (Chairman and MD) and Sachin Mehta (Joint MD) for 1.50 percent each has also been called off. This follows earlier disclosures dated 5 and 15 September 2026 about the proposed acquisition of the US-based biotech company.
Likely market impact
Removes the growth optionality tied to a US biotech acquisition. Deal falling through may be viewed negatively, though no financial commitment details were shared.